Medicines Council still cautious about nevirapine
The fact that one dose may lead to the creation of an HI-virus resistant to Nevirapine is no reason in itself not to register the anti-AIDS drug, but there should be strict monitoring by the drug companies of this, according to Professor Helen Rees chairperson of the Medicines Control Council (MCC).
Addressing parliament’s portfolio health committee on Tuesday (March 27), Rees said the MCC was initially surprised by the high amount of resistance generated by a single dose of Nevirapine to the mother and newborn.
Nevirapine, is currently awaiting MCC registration for use to prevent mother to child transmission of HIV during birth.
“Resistance in itself is not a reason not to register, but how do you monitor that?” Rees asked.She said South Africa would be the first country in the world to register Nevirapine for preventing mother to child transmission.
Rees confirmed that Nevirapine had been approved for use at Government’s 18 pilot sites. She pointed out that one pilot site could be a hospital with several referral clinics.
The pilot sites in all the provinces are supposed to start administering Nevirapine from next week.
In terms of registering the drug for wider use, Rees said the package insert had been approved, but that the MCC was discussing with the company how to tackle the resistance issue.
“In terms of the package insert we were grappling with issues of breastfeeding, having to point out that if women had to breastfeed there could be subsequent HIV transmission.
“In other cases you may have a woman who does not have access to clean water, but is bottle feeding. The baby may develop fatal diarrhoea. What do you say and how do you capture all that in a package insert?”
Rees confirmed that the current MCC’s term of office ended at the end of March and that it was up to the minister to make new appointments or re-appoint current people, including herself.
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Medicines Council still cautious about nevirapine
by Anso Thom, Health-e News
March 30, 2001